Drug Trial Radar · NCT04936308
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Sep 28, 2021
Primary completion
Oct 28, 2024
Study completion Jul 2, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Conditions
- Arthritis, Psoriatic
Interventions
GuselkumabDrug
Participants will receive guselkumab as SC injection.
PlaceboDrug
Participants will receive matching placebo as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24Time frame: At Week 24
Locations
169 sites in 14 countries. Site status is shown where the registry gives one.
Arthritis Associates
Mountain Brook, Alabama
Arizona Arthritis and Rheumatology Research PLLC 2
Avondale, Arizona
Arizona Arthritis and Rheumatology Research PLLC 3
Flagstaff, Arizona
Arizona Arthritis and Rheumatology Research PLLC
Mesa, Arizona
Arizona Arthritis and Rheumatology Research PLLC 1
Phoenix, Arizona
Arizona Arthritis and Rheumatology Associates
Sun City, Arizona
Southern Arizona VA Healthcare System
Tucson, Arizona
Unity Health-White County Medical Center
Searcy, Arkansas
Newport Huntington Medical Group
Huntington Beach, California
Medvin Clinical Research 2
Thousand Oaks, California
Medvin Clinical Research
Tujunga, California
Clinical Research Center of Connecticut
Danbury, Connecticut
Bay Pines VA Healthcare System
Bay Pines, Florida
Clinical Research of West Florida
Clearwater, Florida
Omega Research Consultants
DeBary, Florida
Advanced Clinical Research of Orlando
Ocoee, Florida
Integral Rheumatology And Immunology Specialists
Plantation, Florida
Clinical Research of West Florida 1
Tampa, Florida
Florida Medical Clinic, P.A.
Zephyrhills, Florida
Great Lakes Clinical Trials
Chicago, Illinois
Clinic of Robert Hozman
Skokie, Illinois
The Arthritis and Diabetes Clinic
Monroe, Louisiana
Johns Hopkins University
Baltimore, Maryland
Klein And Associates M D P A
Hagerstown, Maryland
Great Lakes Center of Rheumatology
Lansing, Michigan
Arthritis and Rheumatology Center of MI
Okemos, Michigan
Clinical Research Institute of Michigan, LLC
Saint Clair Shores, Michigan
St. Paul Rheumatology P A
Eagan, Minnesota
Arthritis Consultants
St Louis, Missouri
Arthritis Rheumatic And Back Disease Associates
Voorhees Township, New Jersey
Albuquerque Center for Rheumatology
Albuquerque, New Mexico
Arthritis and Osteoperosis Associates of New Mexico
Las Cruces, New Mexico
Buffalo Rheumatology and Medicine PLLC
Orchard Park, New York
DJL Clinical Research, PLLC
Charlotte, North Carolina
STAT Research, Inc.
Vandalia, Ohio
Health Research of Oklahoma
Oklahoma City, Oklahoma
Rheumatology Associates of Oklahoma
Oklahoma City, Oklahoma
Dr. Ramesh Gupta
Memphis, Tennessee
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Adriana Pop Moody MD Clinic PA
Corpus Christi, Texas
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.